SAN
DIEGO, Feb. 7, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it
will release its fourth quarter and full year 2022 financial and
operating results on Tuesday, February 21,
2023, following the close of trading.
Halozyme will host a conference call on Tuesday, February 21, 2023 at 4:30 p.m. ET/1:30 p.m.
PT to discuss the results. The conference call may be
accessed live with pre-registration via this link:
https://conferencingportals.com/event/QfiVLXsr.
A live webcast and replay of the conference call will also be
available through the "Investors" section of Halozyme's corporate
website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme
rHuPH20, Halozyme's commercially-validated solution is used to
facilitate the delivery of injected drugs and fluids in order to
reduce the treatment burden to patients. Having touched more than
600,000 patient lives in post-marketing use in five commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical
and biotechnology companies including Roche, Takeda, Pfizer,
AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO® and
NOCDURNA® and partnered commercial products and
ongoing product development programs with several pharmaceutical
companies including Teva Pharmaceutical, Covis Pharma, Pfizer and
Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2022-financial-and-operating-results-301739601.html
SOURCE Halozyme Therapeutics, Inc.